French drug maker Sanofi (SNY) announced that its Genzyme unit has begun recruiting patients for a Phase 2/3 study, ASCEND, assessing its enzyme replacement therapy, Breakthrough Therapy-tagged olipudase alfa, for the treatment of patients with non-neurological types of a rare enzyme disorder called acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease type B. The co-primary endpoints are the percent change in spleen volume and the percent change in diffusing capacity of the lung for carbon monoxide from baseline to week 52.